A5071210944- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Platelet Disorders and Treatments
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Hemoglobinopathies and Related Disorders
- Blood groups and transfusion
- Kruppel-like factors research
- Eosinophilic Disorders and Syndromes
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Blood Coagulation and Thrombosis Mechanisms
- Complement system in diseases
- COVID-19 Clinical Research Studies
- Peptidase Inhibition and Analysis
- Iron Metabolism and Disorders
- Neutropenia and Cancer Infections
- Venous Thromboembolism Diagnosis and Management
- Blood disorders and treatments
- Click Chemistry and Applications
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Leprosy Research and Treatment
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
University of Florence
2023
IRCCS Materno Infantile Burlo Garofolo
2015
Universidade Estadual Paulista (Unesp)
2012
University of L'Aquila
2009-2012
Thrombosis Research Institute
2009
University of Bologna
2009
May Institute
2008
Istituto Oncologico Romagnolo
2005
Abstract Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival CML patients has become very close to normal. The next, ambitious, step is bring as many possible into a condition treatment-free remission (TFR). Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA; Italian Group for Hematologic Diseases Adult) Working Party (WP) developed project aimed at...
In patients with cytopenic myelofibrosis, treatment the JAK2/IRAK1 inhibitor pacritinib was associated anemia benefit in phase 3 PERSIST-2 study. The impact of on transfusion independence (TI) has not been previously described, nor mechanism by which improves elucidated. Because it postulated that inhibition activin A receptor, type 1 (ACVR1)/activin receptor-like kinase-2 myelofibrosis via suppression hepcidin production, we assessed relative inhibitory potency compared other JAK2...
Janus kinase (JAK) inhibitors provide limited depth and durability of response in myelofibrosis. We evaluated pelabresib—a bromodomain extraterminal domain (BET) inhibitor—plus ruxolitinib (a JAK inhibitor) compared with placebo plus as first-line therapy. In this phase 3 study (MANIFEST-2), inhibitor-naive patients myelofibrosis were randomized 1:1 to pelabresib 125 mg once daily (QD; 50–175 QD permitted) for 14 days followed by a 7-day break (21-day cycle), or combination 10 15 twice (BID;...
6502 Background: Pelabresib (PELA) is an oral, small-molecule, investigational BET inhibitor that aims to decrease expression of genes involved in MF. MANIFEST-2 (NCT04603495), a global, randomized, double-blind, Phase 3 study, investigated the efficacy and safety PELA + ruxolitinib (PELA+RUX) vs placebo RUX (PBO+RUX) JAKi treatment-naïve patients (pts) with Methods: Eligible pts had DIPSS score ≥ INT-1, platelet count ≥100 × 10 9 /L, spleen volume ≥450 cm , ≥2 symptoms average ≥3 or total...
Abstract Cytotoxic agents like Hydroxyurea, Busulfan and Interferon‐alpha are to date the most commonly used therapeutic approaches in Essential Thrombocythemia (ET). However, few data on efficacy safety of these long‐term currently available. We report a retrospective analysis outcome 386 consecutive ET patients, followed at single Institution for median follow‐up 9.5 years (range, 3–28.5). Cytoreductive therapy was administered 338 patients (88%), obtaining response 86% cases. Forty‐five...
Sorafenib is a multi-targeted kinase inhibitor with demonstrated activity in renal cell carcinoma (RCC) and hepatocellular (HCC), it currently used for the treatment of these pathologies. Ongoing clinical trials are studying its other malignancies, such as non-small-cell lung cancer (NSCLC). However, no biological marker known to define either sensitivity or resistance drug. Here we report case patient two synchronous tumors, HCC NSCLC, metastases contralateral bone. The was treated...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. One open question is whether genetics could influence the severity of symptoms. Considering limited data on cancer patients, we analyzed public repositories to investigate angiotensin-converting enzyme (ACE2) and transmembrane serine protease (TMPRSS2) expressions genetic variants identify basis individual susceptibility SARS-CoV-2.Gene expression variant were retrieved from Tissue Cancer Genome Atlas,...
Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (protocol-defined) or underlying disease (post-hoc) as well efficacy the adjuvanted recombinant vaccine (RZV) in a randomized observer-blind phase III trial (ZOE-HSCT, NCT01610414). 1846 adult auHSCT recipients were to receive first dose either RZV...
Summary Limited information is available on the impact of COVID‐19 pandemic management chronic myeloid leukaemia (CML). The Campus CML network collected retrospective 8 665 patients followed at 46 centres throughout Italy during between February 2020 and January 2021. Within this cohort, we recorded 217 SARS‐CoV‐2‐positive (2·5%). Most (57%) were diagnosed as having SARS‐CoV‐2 infection second peak (September to 2021). majority (35%) was aged 50 65 years with a male prevalence (73%)....
Acute myeloid leukemia (AML) is an incurable disease with fatal infections or relapse being the main causes of death in most cases. In particular, severe occurring these patients before during any treatment suggest intrinsic alteration immune system. this respect, IL-17-producing T helper (Th17) besides playing a key role regulating inflammatory response, tumor growth and autoimmune diseases, have been shown to protect against bacterial fungal pathogens. However, Th17 cells AML has not yet...
Abstract Myeloproliferative neoplasms represent a group of clonal hematopoietic disorders which myelofibrosis (MF) is the most aggressive. In context myeloid neoplasms, there growing recognition dysregulation immune response and T‐cell function as significant contributors to disease progression evasion. We investigated cytotoxic exhaustion in MF restore against malignant cells. Increased expression inhibitory receptors like CTLA‐4 was observed on T cells from patients together with reduced...
In chronic lymphocytic leukemia (CLL) disease onset and progression are influenced by the behavior of specific CD4+ T cell subsets, such as regulatory cells (Tregs). Here, we focused on phenotypic functional characterization Tregs in CLL patients to improve our understanding putative mechanism which these combine immunosuppressive effector-like properties. Peripheral blood mononuclear were isolated from newly diagnosed (n = 25) healthy volunteers 25). The their subsets was assessed flow...
Abstract Iron deficiency anemia is among the most frequent causes of disability. Intravenous iron quickest way to correct deficiency, bypassing bottleneck intestinal absorption, only true mechanism balance regulation in human body. administration suggested patients who are refractory/intolerant oral sulfate. However, intravenous requires several precautions; as in-hospital a resuscitation service, imposed Europe by European Medicine Agency, it very expensive and negatively affects patient’s...
Background: Blood culturing remains the mainstream tool to inform an appropriate treatment in hospital-acquired bloodstream infections and diagnose any bacteremia. Methods: A retrospective investigation on prevalence of Gram-negative bacteria (GNB) their resistance hospitalized patients by age, sex, units from blood cultures (BCs) was conducted January 2018 April 2020 at Sant’Elia hospital, Caltanissetta, southern Italy. We divided patient age range into four equal intervals. Results:...